Clinical Trial Search

Primary: Percentage of Participants With an Adverse Event (AE) — 26.7 percentage of participants

Primary: Change of HbA1c From Baseline at Week 12 — 2.14; 2.10; 1.95; 2.02 ln(percent) — p=<0.0001

Primary: Fatigue Severity Scale (FSS) — 52; 52; 34; 43 units on a scale — p=< 0.001

Primary: Continuous Abstinence Rate (CAR) From Week 9 Through Week 12 — 45.0; 11.8 Percentage of participants — p=<0.0001

Primary: Analgesic Efficacy — 26.5; 32.3 percentage of patients with NRS≥4

Primary: LCM vs CDM: Disease Progression to a New WHO Stage 4 Event or Death — 47; 39 participants — p=0.59

Primary: Change in Hemoglobin (Hgb) Level at Day 2 Post-operatively — -3.73; -3.70 g/dL — p=0.453

Primary: Change in Insulin Sensitivity — 3.2; 2.4 mg/(kg min)

Primary: Clinical Global Impression-Efficacy Index (CGI-EI) — 1.58; 1.52 Units on the scale — p=0.59

Primary: The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint). — 13; 10; 13; 9 participants

Primary: Insertion Time — 26; 18 seconds

Primary: Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) — -.92; .07 percent change in BOLD signal — p=.001

Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) After 14 Weeks Treatment — -0.99; -0.98 percent — p=<0.0001

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 48 — 11.57; 6.43; 16.36 Units on a scale

Primary: Proportion of Subjects Who Were Free From Atrial Arrhythmia at One Year. — 10; 18; 29; 20 participants — p=0.048